KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$30.9 million.

  • Xenon Pharmaceuticals' Net Cash Flow rose 3723.23% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 24967.48%. This contributed to the annual value of -$4.3 million for FY2024, which is 10467.89% down from last year.
  • Xenon Pharmaceuticals' Net Cash Flow amounted to -$30.9 million in Q3 2025, which was up 3723.23% from $18.1 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Net Cash Flow high stood at $254.3 million for Q2 2022, and its period low was -$263.8 million during Q3 2022.
  • Over the past 5 years, Xenon Pharmaceuticals' median Net Cash Flow value was $5.3 million (recorded in 2021), while the average stood at $1.8 million.
  • Examining YoY changes over the last 5 years, Xenon Pharmaceuticals' Net Cash Flow showed a top increase of 542758.69% in 2022 and a maximum decrease of 505306.05% in 2022.
  • Xenon Pharmaceuticals' Net Cash Flow (Quarter) stood at $87.8 million in 2021, then tumbled by 153.59% to -$47.1 million in 2022, then skyrocketed by 203.74% to $48.8 million in 2023, then grew by 15.21% to $56.2 million in 2024, then tumbled by 154.87% to -$30.9 million in 2025.
  • Its Net Cash Flow stands at -$30.9 million for Q3 2025, versus $18.1 million for Q2 2025 and -$26.0 million for Q1 2025.